Litcius/Paper detail

Folate-modified Graphene Oxide as the Drug Delivery System to Load Temozolomide

Lihua Wang, Jiayuan Liu, Lin Sui, Penghui Zhao, Hai-Di Ma, Zhen Wei, Yongli Wang

2020Current Pharmaceutical Biotechnology21 citationsDOI

Abstract

OBJECTIVE: The folate-modified graphene oxide (GO-FA), which had good stability and biocompatibility on rat glioma cells was successfully prepared. METHODS: The formation and composition of GO-FA were confirmed by Scanning Electron Microscope (SEM), Transmission Electron Microscope (TEM), Fourier Transform Infrared Spectrum (FT-IR), Raman spectra and X-ray Photoelectron Spectroscopy (XPS spectra). The cell experiment suggested good biocompatibility of GO-FA on rat glioma cells. RESULTS: The experiment of GO-FA loading with Temozolomide (TMZ) showed that the maximum drug loading of GO-FA was 8.05 ± 0.20 mg/mg, with the drug loading rate of 89.52 ± 0.19 %. When TMZ was released from the folate-modified graphene oxide loading with temozolomide (GO-FATMZ), its release behavior in vitro showed strong pH dependence and sustained release property. The growth of rat glioma cells can be effectively inhibited by GO-FA-TMZ, with the cell inhibition rate as high as 91.72 ± 0.13 % at the concentration of 600 μg/mL and time of 72 h. CONCLUSION: According to the above experimental results, this composite carrier has potential applications in drug delivery and cancer therapy.

Topics & Concepts

TemozolomideGrapheneDrug deliveryDrugOxidePharmacologyChemistryMedicineCancer researchNanotechnologyGlioblastomaMaterials scienceOrganic chemistryGraphene and Nanomaterials ApplicationsCancer Research and TreatmentGraphene research and applications
Folate-modified Graphene Oxide as the Drug Delivery System to Load Temozolomide | Litcius